BioCentury
ARTICLE | Clinical News

CB-5945: Phase III started

November 5, 2012 8:00 AM UTC

Cubist began a double-blind, placebo-controlled, North American Phase III trial to evaluate 0.25 mg oral CB-5945 twice daily for 1 year in about 1,400 patients receiving opioid therapy for chronic non...